Digestive Diseases and Sciences

, Volume 53, Issue 1, pp 163–168 | Cite as

Angiotensin II Type 1 Receptor Expression in Human Gastric Cancer and Induces MMP2 and MMP9 Expression in MKN-28 Cells

  • Wei Huang
  • Li-Fen Yu
  • Jie Zhong
  • Min-Min Qiao
  • Feng-Xiang Jiang
  • Fang Du
  • Xiang-Long Tian
  • Yun-Lin Wu
Original Paper


Angiotensin II (Ang II), a main effector peptide in the renin–angiotensin system, acts as a growth-promoting and angiogenic factor via angiotensin II receptor1 (AT1R). In this study, we investigated the expression of angiotensin II type1 receptor (AT1R) in gastric cancer and the effects of Ang II on the expression of MMP2 and MMP9 in the human gastric cancer cell line MKN-28 cells. The expression of the Ang II type I receptor was examined by western and immunocytochemistry in gastric cancer cell lines and detected by real-time PCR and immunohistochemistry in normal and gastric cancer tissues. The expression of MMP2 and MMP9 were detected by real-time PCR and western after treatment with Ang II and/or AT1R antagonist. AT1R were expressed in all human gastric cancer lines and the expression of AT1R was significantly higher in cancer tissues than that in normal gastric tissues (P < 0.01). Furthermore, Ang II promoted the expression of MMP2 and MMP9 in MKN-28 cells, and the stimulatory effects of Ang II could be blocked by AT1R antagonist. These results suggest that AT1R is involved in the progression of gastric cancer and may promote the angiogenesis of gastric cancer cell line (MKN-28), and these effects may be associated with the upregulation of MMP2 and MMP9.


Gastric cancer Angiotensin II type 1 receptor Matrix metalloproteinases 



The authors thank Dr. Fang Du for the technical assistance. This study was supported by a Grant-in-Aid for the Ministry of Education.


  1. 1.
    Deshayes F, Nahmias C (2005) Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 16(7):293–299PubMedCrossRefGoogle Scholar
  2. 2.
    Ino K, Shibata K, Kajiyama H et al (2006) Manipulating the angiotensin system – new approaches to the treatment of solid tumours. Expert Opin Biol Ther 6(3):243–255PubMedCrossRefGoogle Scholar
  3. 3.
    Escobar E, Rodriguez-Reyna TS, Arrieta O et al (2004) Angiotensin II, cell proliferation and angiogenesis regulator: biologic and therapeutic implications in cancer. Curr Vasc Pharmacol 2(4):385–399PubMedCrossRefGoogle Scholar
  4. 4.
    Deryugina EI, Quigley JP (2006) Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25(1):9–34PubMedCrossRefGoogle Scholar
  5. 5.
    Parsons SL, Watson SA, Collins HM et al (1998) Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy. Br J Cancer 78(11):1495–1502PubMedGoogle Scholar
  6. 6.
    Wang M, Zhang J, Spinetti G et al (2005) Angiotensin II activates matrix metalloproteinase type II and mimics age-associated carotid arterial remodeling in young rats. Am J Pathol 167(5):1429–1442PubMedGoogle Scholar
  7. 7.
    Sawicki G, Menon V, Jugdutt B (2004) Improved balance between TIMP-3 and MMP-9 after regional myocardial ischemia-reperfusion during AT1 receptor blockade. J Card Fail 10(5):442–449PubMedCrossRefGoogle Scholar
  8. 8.
    Williams RN, Parsons SL, Morris TM et al (2005) Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models. Eur J Surg Oncol 31(9):1042–1050PubMedCrossRefGoogle Scholar
  9. 9.
    Dinh DT, Frauman AG, Somers GR et al (2002) Evidence for activation of the renin–angiotensin system in the human prostate: increased angiotensin II and reduced AT(1) receptor expression in benign prostatic hyperplasia. J Pathol 196(2):213–219PubMedCrossRefGoogle Scholar
  10. 10.
    Lam KY, Leung PS (2002) Regulation and expression of a renin–angiotensin system in human pancreas and pancreatic endocrine tumours. Eur J Endocrinol 146(4):567–572PubMedCrossRefGoogle Scholar
  11. 11.
    De Paepe B, Verstraeten VL, De Potter CR et al (2001) Growth stimulatory angiotensin II type-1 receptor is upregulated in breast hyperplasia and in situ carcinoma but not in invasive carcinoma. Histochem Cell Biol 116(3):247–254PubMedGoogle Scholar
  12. 12.
    Takeda H, Kondo S (2001) Differences between squamous cell carcinoma and keratoacanthoma in angiotensin type-1 receptor expression. Am J Pathol 158(5):1633–1637PubMedGoogle Scholar
  13. 13.
    Fujimoto Y, Sasaki T, Tsuchida A et al (2001) Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett 495(3):197–200PubMedCrossRefGoogle Scholar
  14. 14.
    Ino K, Shibata K, Kajiyama H et al (2006) Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival. Br J Cancer 94(4):552–560PubMedCrossRefGoogle Scholar
  15. 15.
    Kikkawa F, Mizuno M, Shibata K et al (2004) Activation of invasiveness of cervical carcinoma cells by angiotensin II. Am J Obstet Gynecol 190(5):1258–1263PubMedCrossRefGoogle Scholar
  16. 16.
    Prontera C, Mariani B, Rossi C et al (1999) Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Int J Cancer 81(5):761–766PubMedCrossRefGoogle Scholar
  17. 17.
    Miyajima A, Kosaka T, Asano T et al (2002) Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 62(15):4176–4179PubMedGoogle Scholar
  18. 18.
    Kondo K, Muramatsu M, Okamoto Y et al (2006) Expression of chymase-positive cells in gastric cancer and its correlation with the angiogenesis. J Surg Oncol 93(1):36–42PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Wei Huang
    • 1
  • Li-Fen Yu
    • 1
  • Jie Zhong
    • 1
  • Min-Min Qiao
    • 1
  • Feng-Xiang Jiang
    • 1
  • Fang Du
    • 2
  • Xiang-Long Tian
    • 1
  • Yun-Lin Wu
    • 1
  1. 1.Department of Gastroenterology, Ruijin HospitalJiaotong University School of MedicineShanghaiChina
  2. 2.Department of immunology, Renji HospitalJiaotong University School of MedicineShanghaiChina

Personalised recommendations